Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 1,889 Shares of Stock

Vir Biotechnology, Inc. (NASDAQ:VIR) EVP Mark Eisner sold 1,889 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $9.82, for a total value of $18,549.98. Following the transaction, the executive vice president directly owned 154,024 shares of the company’s stock, valued at approximately $1,512,515.68. This represents a 1.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Mark Eisner also recently made the following trade(s):

• On Tuesday, February 24th, Mark Eisner sold 1,616 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.53, for a total transaction of $15,400.48.
• On Monday, February 23rd, Mark Eisner sold 2,089 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total transaction of $15,563.05.

Vir Biotechnology Stock Down 6.8%

NASDAQ VIR traded down $0.68 on Thursday, hitting $9.32. 21,297,575 shares of the stock were exchanged, compared to its average volume of 3,752,478. Vir Biotechnology, Inc. has a fifty-two week low of $4.16 and a fifty-two week high of $10.94. The company has a 50-day moving average price of $6.88 and a 200-day moving average price of $6.02. The company has a market cap of $1.30 billion, a PE ratio of -2.95 and a beta of 1.69.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.11. The business had revenue of $64.07 million for the quarter, compared to analyst estimates of $19.91 million. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The company’s revenue was up 417.8% on a year-over-year basis. During the same period last year, the business earned ($0.76) EPS. As a group, equities research analysts predict that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Raymond James Financial raised shares of Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective on the stock in a report on Tuesday. Morgan Stanley increased their target price on shares of Vir Biotechnology from $20.00 to $24.00 and gave the company an “overweight” rating in a research report on Tuesday. Evercore reissued an “outperform” rating and issued a $18.00 price target on shares of Vir Biotechnology in a research report on Tuesday. Leerink Partners reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Vir Biotechnology in a report on Thursday. Finally, Needham & Company LLC lifted their target price on Vir Biotechnology from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Vir Biotechnology presently has an average rating of “Moderate Buy” and an average target price of $19.89.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Corient Private Wealth LLC grew its position in Vir Biotechnology by 1.0% during the 4th quarter. Corient Private Wealth LLC now owns 262,211 shares of the company’s stock worth $1,572,000 after purchasing an additional 2,515 shares during the last quarter. Virtus Investment Advisers LLC boosted its stake in shares of Vir Biotechnology by 82.4% during the fourth quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company’s stock worth $240,000 after buying an additional 17,966 shares during the period. Tudor Investment Corp ET AL acquired a new stake in shares of Vir Biotechnology during the fourth quarter worth about $414,000. Polymer Capital Management US LLC acquired a new stake in shares of Vir Biotechnology during the fourth quarter worth about $202,000. Finally, Quadrature Capital Ltd purchased a new position in shares of Vir Biotechnology during the fourth quarter worth about $300,000. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology News Roundup

Here are the key news stories impacting Vir Biotechnology this week:

• Positive Sentiment: Astellas collaboration materially derisks VIR‑5500 and adds near‑term cash/validation — the global co‑development/co‑commercialization deal includes significant upfront/near‑term payments and up to large milestone upside, boosting the program’s commercial outlook. Astellas and Vir Biotechnology collaborate on VIR-5500
• Positive Sentiment: Updated Phase 1 data for VIR‑5500 show encouraging safety and activity (notable higher‑dose response rates), supporting the asset value that underpins the Astellas deal. VIR-5500 Phase 1 results
• Positive Sentiment: Quarterly beat and revenue surge: Q4 EPS topped estimates and revenue (~$64.1M) far exceeded consensus, helping justify higher analyst targets and fueling recent upside. Vir Q4 earnings highlights
• Positive Sentiment: Analyst support: Needham and other firms raised targets/ratings after the results and deal news, reinforcing bullish institutional views. Needham raises VIR price target
• Neutral Sentiment: Management will be highly visible to investors in March (TD Cowen, Leerink) — useful for clarification on milestones, commercialization plans and cash use. Investor conference participation
• Neutral Sentiment: Media and valuation pieces are amplifying interest and volume — increased coverage raises visibility but doesn’t change fundamentals alone. Valuation after collaboration & Phase 1 update
• Negative Sentiment: Public offering priced: Vir priced 17,647,058 shares at $8.50 (gross proceeds about $150M). Proceeds bolster the balance sheet but the issuance is dilutive and can pressure the stock near term. Public offering priced
• Negative Sentiment: Clustered insider selling: Multiple insiders (CEO, EVPs, CFO, CAO, a director) reported stock sales across Feb. 23–25 — increases visible supply and can weigh on sentiment despite company progress. Insider selling report
• Negative Sentiment: Ongoing losses: Despite revenue growth and partnership cash, Vir reported a sizable net loss and wide negative margins — long‑term upside depends on execution, milestones and commercial ramp. 2025 financial results

About Vir Biotechnology

Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.